Business Wire

AXON’s AADvac1 Tau Vaccine One of the Hot Topics at CTAD 2015 Conference

Del

AXON Neuroscience presented encouraging Phase 1 study results of the company’s active tau vaccine AADvac1 at the opening session of the 8th International Conference on Clinical Trials in Alzheimer’s Disease (CTAD). At the session, called Hot Topics in AD Clinical Trials, AXON demonstrated an excellent safety and immunogenicity profile of the AADvac1 from the finished Phase 1 study. AXON’s second presentation at CTAD presented the exceptional preclinical results of the passive vaccine AADvac2, another lead compound of the company.

AADVAC1 TAU ACTIVE THERAPY

AXON’s vaccine AADvac1 stimulates patients’ immune systems to generate specific antibodies against diseased forms of tau protein and thus protect the brain from neurodegeneration. The vaccine is intended to be a disease-modifying drug for Alzheimer’s disease.

At the CTAD 2015 presentation, AXON’s Medical Director, Matej Ondrus, showed that the AADvac1 vaccine is safe and well tolerated in all assessed parameters. Additionally, the treatment induced a robust immune response in the vast majority of the study participants and the average cognition of patients remained stable over 6 months.

After the presentation, Prof. Michal Novak, Chairman of the Scientific Advisory Board at AXON Neuroscience, added: “We expect the Phase II study to begin by the end of 2015. This should allow us to confirm the promising results also on a large patient population, targeting mild Alzheimer’s disease.”

AADVAC2 PASSIVE IMMUNOTHERAPY

AXON Neuroscience´s passive vaccine AADvac2 is a humanized monoclonal antibody that was created as a genuine structural imprint of a diseased form of tau protein isolated from Alzheimer’s disease. The antibody recognized the target area on tau, which plays an important role in pathological communication between tau proteins in the brain suffering from Alzheimer’s disease. The antibody is able to inhibit formation of neurofibrillary tangles, the hallmark of AD, and eliminates pathological tau phosphorylation.

AXON NEUROSCIENCE

AXON Neuroscience is a clinical-stage biotech company developing disease-modifying immunotherapeutics for Alzheimer's disease and other tauopathies. The company employs the largest scientific team worldwide focusing exclusively on tau protein and tau-related neurodegenerative disorders.

Contact information

AXON Neuroscience
Michael Matis
+421 902 161 362
media@axon-neuroscience.eu

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Equifax Integrates Entersekt’s Digital Security System22.2.2018 12:35Pressemelding

Entersekt, a leader in push-based authentication and mobile app security, today announced a technology partnership with global information solutions company Equifax Inc. (NYSE:EFX). Equifax has licensed Entersekt’s product Transakt to serve as an additional layer of security protecting the Equifax online and mobile services. Transakt empowers consumers to play an active role in safeguarding their digital identities and accounts. Whenever access to a digital identity or account is required, an authentication request is pushed to their phone or tablet in real time. They approve or block access by simply tapping Accept or Reject. It’s a highly intuitive, one-touch user experience engineered for a mobile-first world. Transakt’s ease of use belies its advanced set of security features. Covered by 56 patents in the United States and elsewhere, the digital-certificate–based technology uniquely identifies each registered mobile device; ensures its continued integrity as a factor of authenticat

ImmerVision to Showcase AI-Ready Vision Technology at MWC 201822.2.2018 12:00Pressemelding

ImmerVision, a technology company enabling intelligent vision in all the world’s devices, announced today that it is uniquely prepared to provide AI-ready, data-rich image processing to today’s most incisive device makers and manufacturers. Indeed, ImmerVision is already providing such hyper-intelligent image capture capabilities to some of the world’s top brands. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180222005513/en/ ImmerVision Enables AI-ready intelligent devices include Acer Holo360, Quanta Pi SOLO, and Tamaggo 360LiveCam (Graphic: Business Wire) Based in Montreal, Canada, ImmerVision develops wide-angle panomorph lenses and data-augmented imaging algorithms, enabling creative manufacturers to see more and smarter while creating professional and consumer devices. “In our quest to enable intelligent vision in every device, ImmerVision has taken a great leap forward,” says Alessandro Gasparini, Executive Vice Presi

Kite, a Gilead Company, and Sangamo Therapeutics Announce Collaboration to Develop Next-Generation Engineered Cell Therapies for the Treatment of Cancer22.2.2018 12:00Pressemelding

Kite, a Gilead Company (Nasdaq:GILD) and Sangamo Therapeutics, Inc. (Nasdaq:SGMO) today announced the companies have entered into a worldwide collaboration using Sangamo’s zinc finger nuclease (ZFN) technology platform for the development of next-generation ex vivo cell therapies in oncology. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180222005488/en/ Kite will use Sangamo’s ZFN technology to modify genes to develop next-generation cell therapies for autologous and allogeneic use in treating different cancers. Allogeneic cell therapies from healthy donor cells or from renewable stem cells would provide a potential treatment option that can be accessed directly within the oncology infusion center, thus reducing the time to infusion for patients. Under the terms of the agreement, Sangamo will receive an upfront payment of $150 million and is eligible to receive up to $3.01 billion in potential payments, aggregated across 10

CorFlow Presents Fundamental New Insights into the Coronary Microcirculation at ACC22.2.2018 09:10Pressemelding

CorFlow Therapeutics AG (www.corflow-therapeutics.ch) today announced that the company will present fundamental new insights into the coronary microcirculation during the annual meeting of the American College of Cardiology (ACC) in Orlando, FL, March 10-12, 2018. CorFlow has since its foundation in June 2016 worked to document that the Controlled Flow Infusion (CoFITM) technology is able to measure the coronary microvascular status and provide therapy to the compromised coronary microcirculation at the same time. Microvascular obstruction (MVO) affects more than half of the acute heart attack patients and is an independent predictor for complications including heart failure which constitutes a high cost burden for the world-wide health care system. To address this large unmet medical need in interventional cardiology, CorFlow has developed an in-vivo model which reproducibly creates MVO in an occlusion-reperfusion model with very low complication rates. Using this in-vivo model, the C

DocsCorp White Paper Encourages Businesses to Review their 2018 Data Protection Strategy – Protection through Technology22.2.2018 09:02Pressemelding

Tough new data protection laws are coming – are you prepared? Reviewing your data protection strategy in 2018, a new white paper published today by DocsCorp, challenges readers to assess their readiness to comply with rigorous upcoming data protection standards affecting businesses in Europe, the Americas and Australia. DocsCorp contends that organizations around the world will be affected by new data laws. The UK’s General Data Protection Regulation (GDPR) goes into force in May 2018. Australia’s new, sweeping National Data Breach (NDB) notification laws already require all businesses to report data breaches. In the United States, many individual states have passed their own data protection laws, and the US federal government has proposed the nationwide Data Security and Breach Notification Act, currently under congressional review. A main focus of GDPR is “Privacy by Design and Default,” which recommends preventative action before breaches occur rather than coping with damages and pe

GSMA Warns That Policymakers Must Act Now to Avoid Mobile Network “Gridlock” in Major Cities22.2.2018 09:00Pressemelding

The GSMA today published a new report that examines the ability of mobile networks to meet the exploding demand for mobile data in the world’s largest and densest cities. The GSMA/Boston Consulting Group report, “Delivering the Digital Revolution: Will Mobile Infrastructure Keep Up with Rising Demand?”, finds that networks in so-called “megacities” such as New York, Shanghai, Shenzhen and Tokyo will face a significant gap between mobile data traffic demand and available network capacity, with as much as 48 per cent of traffic demand going unserved in ultra-dense urban areas by 2025. The report highlights that regulatory reform will be critical in closing the projected supply-demand gap and unlocking the economic potential of next-generation mobile broadband. “The current global regulatory landscape has been successful in creating a competitive market that has made mobile connectivity accessible to more than five billion people around the world,” said John Giusti, Chief Regulatory Offic